Identification of HIV-1 Restriction Factors through Functional Genomic Screens

通过功能基因组筛选鉴定 HIV-1 限制因素

基本信息

  • 批准号:
    8432608
  • 负责人:
  • 金额:
    $ 1.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-14 至 2013-10-01
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): HIV requires host machinery to replicate. In turn, the host cell protects itself using antiviral factors. A full understanding of the host factors involve in HIV replication will provide us with valuable knowledge of HIV virology and cell biology. It will also help to develop new anti-HIV therapy. Functional screens using genome-wide siRNA libraries have implicated hundreds of host proteins as modulators of HIV replication. In this proposed project, we will use multiple RNAi resources to identify the innate host proteins that restrict HIV-1 replication. The remaining goals for this project are to focus on further validation and functional study of the restriction factors that come out of screens. Aim 1 is the validation and functional analysis of HIV-1 restriction factors identified through genome-wide siRNA screens. We recently completed siRNA screens using multiple RNAi resources (three orthologous siRNA libraries). The screens identified 212 potential host restriction factors. For this aim, we plan to focus on a shortened list of potential anti-HIV host factors, and perform further validation and functional studies to confirm their roles. The plan includes confirmation of siRNA knockdown efficacy, RNAi effect rescue, validation in human primary cells, and mechanistic studies of a few of promising HIV-1 restriction factors. In addition, we plan to test the inhibitory efforts of confirmed restriction factors on other viruses. Aim 2 is the identificatin of factors that mediate interferon- induced restriction of HIV-1 through genome-wide siRNA screens. It has been long known that Type I interferon (IFN) can induce the expression of a large set of interferon-stimulated genes and establish a potent antiviral response. Both early and late steps of HIV-1 replication can be blocked by IFN-1. In this aim, we will perform genome-wide siRNA screens to identify HIV-1 restriction factors whose activity is required by IFN. The candidate restriction factors will be further filtered by performing comprehensive bioinformatic analysis. A set of potential IFN-induced HIV-1 restriction factors will be selected for further validation and functional studies. We believe that our study of HIV-1 restriction factors will provide new insights into the barriers to viral infection and may have important ramifications for the identification of new antiviral targets.
描述(申请人提供):艾滋病毒需要宿主机器进行复制。反过来,宿主细胞使用抗病毒因子来保护自己。充分了解艾滋病毒复制所涉及的宿主因素将为我们提供有关艾滋病毒病毒学和细胞生物学的宝贵知识。它还将有助于开发新的抗艾滋病毒疗法。使用全基因组siRNA文库的功能筛选表明,数百种宿主蛋白是艾滋病毒复制的调节器。在这个拟议的项目中,我们将使用多种RNAi资源来识别限制HIV-1复制的固有宿主蛋白。该项目的剩余目标是专注于进一步的验证 以及筛选出来的制约因素的功能研究。目的1是通过全基因组siRNA筛选确定的HIV-1限制因子的验证和功能分析。我们最近使用多个RNAi资源(三个同源siRNA文库)完成了siRNA筛选。筛选确定了212个潜在的寄主限制因素。为此,我们计划专注于一系列潜在的抗HIV宿主因子,并进行进一步的验证和功能研究,以确认它们的作用。该计划包括确认 SiRNA敲除效率,RNAi效应拯救,在人类原代细胞中的验证,以及几个有希望的HIV-1限制因子的机制研究。此外,我们计划测试已证实的限制因子对其他病毒的抑制作用。目的2是通过全基因组siRNA筛选鉴定介导干扰素诱导的HIV-1限制的因素。众所周知,I型干扰素可以诱导大量干扰素刺激基因的表达,并建立有效的抗病毒反应。HIV-1复制的早期和晚期都可以被干扰素-1阻断。为此,我们将进行全基因组siRNA筛选,以确定干扰素所需的HIV-1限制因子的活性。通过进行全面的生物信息学分析,将进一步筛选候选限制因素。一组潜在的干扰素诱导的HIV-1限制因子将被选择用于进一步的验证和功能研究。我们相信,我们对HIV-1限制因子的研究将为病毒感染的障碍提供新的见解,并可能对识别新的抗病毒靶点产生重要影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jian Zhu其他文献

Jian Zhu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jian Zhu', 18)}}的其他基金

Role of RNA Methylation in Regulating HIV Proviral Expression
RNA 甲基化在调节 HIV 原病毒表达中的作用
  • 批准号:
    10426418
  • 财政年份:
    2021
  • 资助金额:
    $ 1.59万
  • 项目类别:
Role of FACT Proteins in Regulating HIV Transcription and Latency
FACT 蛋白在调节 HIV 转录和潜伏期中的作用
  • 批准号:
    9335501
  • 财政年份:
    2015
  • 资助金额:
    $ 1.59万
  • 项目类别:
Investigation of Latency Promoting Genes (LPGs) in HIV Oral Reservoir Cells
HIV 口腔储存细胞潜伏期促进基因 (LPG) 的研究
  • 批准号:
    9283243
  • 财政年份:
    2015
  • 资助金额:
    $ 1.59万
  • 项目类别:
Role of FACT Proteins in Regulating HIV Transcription and Latency
FACT 蛋白在调节 HIV 转录和潜伏期中的作用
  • 批准号:
    9716746
  • 财政年份:
    2015
  • 资助金额:
    $ 1.59万
  • 项目类别:
Role of FACT Proteins in Regulating HIV Transcription and Latency
FACT 蛋白在调节 HIV 转录和潜伏期中的作用
  • 批准号:
    9139906
  • 财政年份:
    2015
  • 资助金额:
    $ 1.59万
  • 项目类别:
Role of FACT Proteins in Regulating HIV Transcription and Latency
FACT 蛋白在调节 HIV 转录和潜伏期中的作用
  • 批准号:
    8920866
  • 财政年份:
    2015
  • 资助金额:
    $ 1.59万
  • 项目类别:
Cooperation of BRD4 and TAT Associated Proteins in HIV Transcription and Latency
BRD4 和 TAT 相关蛋白在 HIV 转录和潜伏期中的合作
  • 批准号:
    8841576
  • 财政年份:
    2014
  • 资助金额:
    $ 1.59万
  • 项目类别:
Cooperation of BRD4 and TAT Associated Proteins in HIV Transcription and Latency
BRD4 和 TAT 相关蛋白在 HIV 转录和潜伏期中的合作
  • 批准号:
    9319617
  • 财政年份:
    2014
  • 资助金额:
    $ 1.59万
  • 项目类别:
Identification of HIV-1 Restriction Factors through Functional Genomic Screens
通过功能基因组筛选鉴定 HIV-1 限制因素
  • 批准号:
    8255929
  • 财政年份:
    2012
  • 资助金额:
    $ 1.59万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 1.59万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 1.59万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 1.59万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 1.59万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 1.59万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 1.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 1.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了